Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study

被引：0

作者：

Kavanaugh, Arthur ^{[1
]}

Soriano, Enrique ^{[2
,3
]}

Dutz, Jan ^{[4
]}

Selmi, Carlo ^{[5
]}

Rampakakis, Emmanouil ^{[6
]}

Shiff, Natalie ^{[7
]}

Nantel, Francois ^{[8
]}

Lavie, Frederic ^{[9
]}

Coates, Laura ^{[10
]}

机构：

[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA USA

[2] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina

[3] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina

[4] Vancouver Gen Hosp, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

[5] Humanitas Univ, Humanitas Res Hosp Internal Med, Rheumatol & Clin Immunol, Rozzano, Italy

[6] McGill Univ, JSS Med Res, Sci Affairs, Dept Pediat, Montreal, PQ, Canada

[7] Univ Saskatchewan, Immunol, Janssen Sci Affairs LLC Adjunct, Horsham, PA USA

[8] Nantel Medsci Consult, Montreal, PQ, Canada

[9] Janssen Pharmaceut Companies Johnson & Johnson, Paris, France

[10] Univ Oxford, Oxford, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

BIOLOGIC-NAIVE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2238

引用

页码：4421 / 4424

页数：4

共 50 条

[1] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Adelakun, Oyediran
Rampakakis, Emmanouil
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
[2] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
Ritchlin, Christopher T.
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Rampakakis, Emmanouil
Chakravarty, Soumya
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[3] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Felten, Renaud
Widawski, Laura
Spielman, Lionel
Gottenberg, Jacques-Eric
Duret, Pierre-Marie
Rampakakis, Emmanouil
Sharaf, Mohamed
Constantin, Caren
Campana, Vincenza
Messer, Laurent
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
[4] GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDIES
Kavanaugh, A.
Soriano, E.
Dutz, J.
Selmi, C.
Yu, J.
Rampakakis, E.
Shawi, M.
Bravo Perdomo, A. M.
Lavie, F.
Coates, L.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1770 - 1771
[5] SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
Nielsen, S. Holm
Bay-Jensen, A. C.
Frederiksen, P.
Karsdal, M.
Shawi, M.
Chakravarty, S. D.
Kollmeier, A.
Chen, W.
Gao, S.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 342 - 343
[6] Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Nielsen, Signe Holm
Bay-Jensen, Anne-Christine
Frederiksen, Peder
Karsdal, Morten
Shawi, May
Chakravarty, Soumya
Kollmeier, Alexa
Chen, Warner
Gao, Sheng
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4219 - 4220
[7] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Deodhar, Atul
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth C.
LANCET, 2018, 391 (10136): : 2213 - 2224
[8] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Coates, Laura C.
Gossec, Laure
Zimmermann, Miriam
Shawi, May
Rampakakis, Emmanouil
Shiff, Natalie J.
Kollmeier, Alexa P.
Xu, Xie L.
Nash, Peter
Mease, Philip J.
Helliwell, Philip S.
RMD OPEN, 2024, 10 (01):
[9] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher T.
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Chakravarty, Soumya D.
Rampakakis, Emmanouil
Shawi, May
Merola, Joseph F.
McInnes, Iain B.
Deodhar, Atul
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB225 - AB225
[10] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Coates, Laura C.
Rahman, Proton
Mease, Philip J.
Shawi, May
Rampakakis, Emmanouil
Kollmeier, Alexa P.
Xu, Xie L.
Chakravarty, Soumya D.
McInnes, Iain B.
Tam, Lai-Shan
BMC RHEUMATOLOGY, 2024, 8 (01)

← 1 2 3 4 5 →